Document Detail


Effects of dietary magnesium supplementation on diurnal variations of blood pressure and plasma Na+, K(+)-ATPase activity in essential hypertension.
MedLine Citation:
PMID:  1338597     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
To evaluate the antihypertensive and hormonal effects of oral magnesium supplementation, 17 inpatients with untreated, uncomplicated mild-to-moderate essential hypertension (EH) and 8 age-matched normotensive controls (controls) were given MgO orally 3 times a day at a daily dose of 1.0 g (0.6 g per day as Mg) for a period of 2 weeks. Supplementation of MgO elicited a significant fall in averaged mean blood pressure calculated with a 24-h ambulatory blood pressure monitoring system (MBP) in EH from a baseline value of 104.3 +/- 12.2 to 99.5 +/- 11.6 mmHg (p < 0.05), while controls remained unaltered from a baseline value of 85.1 +/- 11.5 to 84.5 +/- 13.3 mmHg. The percentage reductions in systolic and diastolic blood pressures were similar during daytime and nighttime in EH. According to the extent of reduction in MBP with magnesium supplementation, EH patients were divided into 2 groups, responder and nonresponder. The level of plasma renin activity (PRA) in the responder group was significantly higher than that of the nonresponder group (p < 0.05). After 2 weeks of magnesium supplementation, the plasma level of Na+, K(+)-ATPase inhibitory activity (PATPI), defined as equivalency to ouabain, was reduced significantly from 0.75 +/- 0.54 to 0.40 +/- 0.30 mumol ouabain/ml (p < 0.05) in the responder group, while it remained unaltered in controls and the nonresponder group. PRA, plasma aldosterone concentration, urinary epinephrine and norepinephrine excretion, and urinary sodium excretion did not change significantly in either control subjects or EH (responder and nonresponder groups). A significant negative correlation existed between the pretreatment PRA and changes in MBP after magnesium supplementation in EH (r = -0.65, p < 0.01), and there was a significant positive correlation between changes in PATPI and changes in MBP as a whole (r = 0.41, p < 0.05). These results support the view that oral magnesium supplementation is a useful approach to treatment of patients with uncomplicated essential hypertension, especially those with high plasmas renin activity. It appears that magnesium suppresses circulating Na+,K(+)-ATPase inhibitory activity to attenuate vascular tone, and thereby reduces blood pressure in EH.
Authors:
H Haga
Related Documents :
7018237 - Low and high renin essential hypertension: a comparison of clinical and biochemical cha...
10651217 - Low renin hypertension in the next millennium.
1022407 - The renin-angiotensin systems in adrenal-regeneration hypertension.
8596377 - 15-year follow-up of renin and blood pressure in reflux nephropathy.
16159857 - Annular height-to-commissural width ratio of annulolasty rings in vivo.
8400757 - Rate of cerebrospinal fluid formation, resistance to reabsorption of cerebrospinal flui...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Japanese heart journal     Volume:  33     ISSN:  0021-4868     ISO Abbreviation:  Jpn Heart J     Publication Date:  1992 Nov 
Date Detail:
Created Date:  1993-05-14     Completed Date:  1993-05-14     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0401175     Medline TA:  Jpn Heart J     Country:  JAPAN    
Other Details:
Languages:  eng     Pagination:  785-800     Citation Subset:  IM    
Affiliation:
Third Department of Internal Medicine, Fukushima Medical College, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aldosterone / blood
Blood Pressure / drug effects*
Circadian Rhythm / drug effects*
Female
Humans
Hypertension / blood,  diet therapy*,  physiopathology*
Magnesium / administration & dosage*,  blood,  therapeutic use
Male
Middle Aged
Renin / blood
Sodium-Potassium-Exchanging ATPase / blood*
Chemical
Reg. No./Substance:
52-39-1/Aldosterone; 7439-95-4/Magnesium; EC 3.4.23.15/Renin; EC 3.6.3.9/Sodium-Potassium-Exchanging ATPase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs...
Next Document:  Anti-polynuclear neutrophil cytoplasmic antibodies of the perinuclear type or p-ANCA